Can aflatoxin B1 or ochratoxin A cause neurotoxic oxidative and inflammatory effects, while urinary detection still fails to prove neurologic disease or amyloid causation in one patient?

Aflatoxin B1 (AFB1) and ochratoxin A (OTA) are biologically plausible neurotoxicants in experimental systems, but this does not make a urinary mycotoxin result diagnostic of neurologic disease or amyloid pathology in a 69-year-old individual.

Experimental neurotoxicity and mechanisms

• AFB1: Oral 30–90-day rat exposure reduced antioxidant defenses and increased lipid peroxidation/protein carbonyls, alongside necrosis and astrocyte gliosis. A 21-day mouse drinking-water study found microglial activation, increased inflammatory cytokines, and NF-κB activation. Cell studies also associate AFB1 with ROS generation, DNA damage, and apoptosis; acute mouse exposure produced dose-dependent oxidative DNA damage across brain regions.
• OTA: Experimental evidence includes dose-dependent striatal dopamine depletion and oxidative DNA damage after acute mouse exposure. Repeated rat dosing has been associated with memory/behavioral deficits, hippocampal lesions, and gliosis. Neural-cell models show pro-inflammatory, M1-like microglial responses, although the in-vivo inflammatory-neurotoxicity linkage is less directly established than for AFB1.
• These findings support oxidative stress, DNA injury, glial activation, cytokine signaling, and NF-κB-related inflammation as plausible mechanisms. Effects vary substantially by administered dose, route, and duration.

Interpretation of urine findings

• Urinary AFB1/AFM1 or OTA can support evidence of recent exposure, not individual dose, chronicity, source, brain concentration, or toxicity. Results are influenced by timing of collection, urine dilution, metabolism, and the analyte measured.
• No human studies link these urinary biomarkers to neurologic imaging, cognitive outcomes, incident neurologic disease, amyloid PET, CSF amyloid/tau, neuropathology, or Alzheimer disease. CDC notes that no FDA-approved urine mycotoxin test or urine threshold predicts illness.

Bottom line

• Experimental neurotoxicity is credible, especially for AFB1, but a positive urine test cannot prove that neurologic symptoms—or amyloid pathology—were caused by either mycotoxin. Persistent cognitive or neurologic symptoms require standard clinical evaluation; exposure assessment may guide environmental investigation but cannot replace diagnosis.